2160 Stock Overview
MicroPort CardioFlow Medtech Corporation, a medical device company, engages in the research, development, and commercialization of transcatheter and surgical solutions for structural heart diseases in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2160 from our risk checks.
MicroPort CardioFlow Medtech Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.11 |
| 52 Week High | HK$2.49 |
| 52 Week Low | HK$0.85 |
| Beta | 0.38 |
| 1 Month Change | 20.65% |
| 3 Month Change | -9.02% |
| 1 Year Change | -52.36% |
| 3 Year Change | -92.97% |
| 5 Year Change | n/a |
| Change since IPO | -94.10% |
Recent News & Updates
Recent updates
MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Apr 05
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
Feb 23An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued
Jan 18Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth
Oct 04Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%
May 31We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
May 23The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts
Apr 06MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans
Feb 08We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
Oct 18We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate
Jun 30Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts
Apr 04MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Apr 03An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued
Jan 21Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?
Sep 05We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn
Jun 07Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)
May 03Shareholder Returns
| 2160 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 7.8% | 4.8% | 2.2% |
| 1Y | -52.4% | -45.4% | -7.9% |
Return vs Industry: 2160 underperformed the Hong Kong Medical Equipment industry which returned -44.8% over the past year.
Return vs Market: 2160 underperformed the Hong Kong Market which returned -8.1% over the past year.
Price Volatility
| 2160 volatility | |
|---|---|
| 2160 Average Weekly Movement | 8.7% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2160's share price has been volatile over the past 3 months.
Volatility Over Time: 2160's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 592 | Jeffrey R Lindstrom | www.cardioflowmedtech.com |
MicroPort CardioFlow Medtech Corporation, a medical device company, engages in the research, development, and commercialization of transcatheter and surgical solutions for structural heart diseases in the People’s Republic of China. It offers Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set to target aortic, mitral, tricuspid, and surgical valves, as well as procedural accessories. The company was founded in 2010 and is headquartered in Shanghai, China.
MicroPort CardioFlow Medtech Corporation Fundamentals Summary
| 2160 fundamental statistics | |
|---|---|
| Market cap | HK$2.68b |
| Earnings (TTM) | -HK$509.14m |
| Revenue (TTM) | HK$363.03m |
7.4x
P/S Ratio-5.3x
P/E RatioIs 2160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2160 income statement (TTM) | |
|---|---|
| Revenue | CN¥336.22m |
| Cost of Revenue | CN¥106.28m |
| Gross Profit | CN¥229.93m |
| Other Expenses | CN¥701.47m |
| Earnings | -CN¥471.53m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 68.39% |
| Net Profit Margin | -140.25% |
| Debt/Equity Ratio | 0% |
How did 2160 perform over the long term?
See historical performance and comparison